Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is a leader in various therapeutic areas, with its key products including Verzenio, Jaypirca, Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, Humulin, Taltz, and Olumiant. The company's performance in the second quarter of 2026 was above expectations, with revenue of $20.7 billion (beating consensus of $20.5 billion), driven by strong sales of its cancer, cardiometabolic, and immunology products. With upcoming catalysts, such as the FDA approval and launch of Foundayo in the US and potential UK launch, the company's revenue is expected to continue to grow. Furthermore, Eli Lilly's focus on sustainability and its promising pipeline, including eloralintide for obesity and other genetic GLP-1 resistant patients, generate positive expectations for long-term growth and differentiation in the pharmaceutical industry.

Bears say

Eli Lilly is facing several challenges, including slow uptake of its new products like Foundayo and pricing pressures on its key product, Tirzepatide. The company may also face difficulties in meeting enrollment targets for clinical trials, particularly in underrepresented populations. Additionally, competition from novel therapies and concerns about high multiples could put pressure on the company's stock. To address these challenges, Eli Lilly should articulate specific enrollment targets and community partnership strategies for pivotal trials, establish differentiated pricing for lower-income markets, and provide more clarity on allocation principles and access commitments.

Eli Lilly (LLY) has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 20 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,296.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,296.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.